ITGAX and melanoma: To further support the above analyses, TxflSig, TxflSig1, ITGAL, ITGAX, and IIT all predicted OS probabilities in multiple cohorts treated with ICB, including melanoma and clear-cell renal cell carcinoma (ccRCC) (Figure 3D–H and Figure S3).